Source Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Florida College of Medicine, 1600 South West Archer Road, Room HD 602, PO Box 100214, Gainesville, FL 32610, USA.
Recurrence of hepatitis C virus remains a near-universal phenomenon after liver transplantation (LT) and is responsible for the high morbidity and low survival seen in these patients. The severity of recurrent disease varies depending on multiple factors, only some of which are modifiable. Antiviral therapy is associated with improved outcomes, but viral clearance is only attainable in a small percentage of this patient population. This patient population is in need of new therapeutic options, and it remains to be seen whether direct-acting antiviral agents will be the answer to this ongoing therapeutic question.